Moderna Shares Plummet Following Leak of Melanoma Vaccine Trial Data
What happened
Moderna shares plummeted after leaked Phase 3 trial data for its melanoma vaccine fell short of Wall Street expectations.
The Context
- Data Leak: The trial results were prematurely released via Oncology Central, leading to chaotic trading and a swift market reaction.
- Efficacy Results: The mRNA vaccine combined with Keytruda showed a 42% reduction in recurrence or death, aligning with prior signals but disappointing investor expectations.
- Market Impact: Moderna's stock dropped as much as 25% intraday, erasing approximately $24 billion in market capitalization, while Merck's shares dipped modestly.
The Number
— This peak intraday decline in Moderna shares highlights the volatility and risk associated with biotech investments, particularly around clinical trial outcomes.
Takeaway
As the market stabilizes, focus will shift to upcoming presentations and the implications for future cancer therapies.
Editor-curated FT homepage stories spanning markets, business, world, and opinion.
"The Financial Times is a globally respected business publication with a centrist/center-left tone and strong markets focus."
— A47 Editor
Moderna shares sink after leaked cancer data missed expectations
Moderna's shares experienced a significant decline after the company announced that its melanoma vaccine treatment, which reduced the risk of recurrence or death by 58%, did not meet Wall Street's high expectations. This news led to a drop in investo...
Stock market news, investing ideas, and trading analysis.
"TheStreet provides market news and retail-investor-focused analysis."
— A47 Editor
Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says
Moderna's stock experienced a significant 17% decline following the leak of trial data for its personalized mRNA cancer vaccine, developed in collaboration with Merck, which showed promising results but failed to meet Wall Street's high expectations.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Moderna shares plunged after details from a closely guarded mRNA-based cancer vaccine study were shared on social media
Moderna's shares experienced a significant decline after confidential details from a study on its mRNA-based cancer vaccine were leaked on social media ahead of an anticipated conference. The study was expected to provide critical insights into the v...
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media
Moderna's stock experienced a significant decline of up to 25% following the unauthorized sharing of data from a closely guarded study regarding its personalized mRNA cancer vaccine. This data was expected to be formally presented at an upcoming conf...
Global business headlines with AI angles.
"General business outlet that frequently covers AI."
— A47 Editor
Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.
Moderna's stock plummeted by up to 25% following the leak of data regarding its experimental cancer vaccine, despite the information being more favorable than Wall Street's expectations. This unexpected decline raises concerns about investor confiden...
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak
Moderna's stock plummeted by 25% following a potential data leak regarding its personalized cancer vaccine, marking a significant downturn after a previously strong stock rally in 2026 driven by optimism about the vaccine's prospects.